In this context, this measurement could help to stratify CF patients carrying CFTR mutations with unknown functional consequences for treatment with CFTR potentiator or corrector drugs, and also pre-assess which patients will be ‘responders’ to a given drug by determining its therapeutic effects on CFTR function directly in native tissues from each individual CF patient. The gene discussed is CFTR; the disease is cystic fibrosis.